International Registry of Congenital Portosystemic Shunt (IRCPSS)

Study summary

Congenital Portosystemic Shunt (CPSS) is a rare condition important by the multiplicity and severity of associated complications. CPSS is venous anomaly in which blood coming from the intestines only partially passes through the liver. This leads to the accumulation of potentially toxic factors that cause systemic effects. Complications vary among the individuals, and currently, it is challenging to predict which individuals will develop severe complications. The IRCPSS registry is established with the aim of centralizing detailed clinical follow-up and biological information from participants around the world who suffer from Congenital Portosystemic Shunt (CPSS). A multidisciplinary consortium of experts is collaborating to enhance our understanding of the prevalence, natural history, individual risks, and physiopathology of the disease through the IRCPSS registry.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedShunt Closure

The study team can explain what participation involves.

Who it may be forCongenital Portosystemic Shunt · CPSS (Congenital Portosystemic Shunt)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 18, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Enrolling By Invitation

Participation is limited to people invited by the study team.

What kind of study?Not applicable

Observational

Where is it offered?26 U.S. locations

Locations may change over time.

Who runs it?Prof. Valérie Mc Lin

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Prof. Valérie Mc Lin
Interventions being studied: Procedure: Shunt Closure

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Individual with CPSS

Reasons someone may not be able to joinExclusion criteria

Secondary shunt without evidence of congenital shunt

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Yale University School of MedicineNew Haven, Connecticut
Lurie Children's HospitalChicago, Illinois
Royal Children's Hospital MelbourneParkville, Victoria
Universitary Clinics Saint-Luc, UCLBrussels
The Hospital for Sick ChildrenToronto, Ontario
Beaujon University HospitalClichy
Hôpital Bicêtre-Hôpitaux Universitaires Paris-Sud- Assistance Publique Hôpitaux de Paris.Le Kremlin-Bicêtre
Hôpital NeckerParis
Hannover Medical SchoolHanover
Haunersche Kinderklinik - LMU MunichMunich
University of TuebingenTübingen
First Department of Pediatrics, Semmelweis UniversityBudapest

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 18, 2025. Always confirm current availability with the study team.

View original record ↗